Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells  by Sarnataro, Daniela et al.
FEBS 30104 FEBS Letters 579 (2005) 6343–6349Plasma membrane and lysosomal localization of CB1
cannabinoid receptor are dependent on lipid rafts and regulated
by anandamide in human breast cancer cells
Daniela Sarnataroa,b,1, Claudia Grimaldia,1, Simona Pisantia, Patrizia Gazzerroa, Chiara Laezzac,
Chiara Zurzolob,d, Maurizio Bifulcoa,b,*
a Dip.di Scienze Farmaceutiche, Universita` degli Studi di Salerno, Italy
b Dip. Biologia e Patol. Cell. Mol., Universita` degli Studi di Napoli Federico II, Napoli, Italy
c IEOS, CNR Napoli, Italy
d Unite´ de Traﬁc Membranaire et Pathoge´ne`se, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France
Received 7 September 2005; revised 10 October 2005; accepted 11 October 2005
Available online 24 October 2005
Edited by Sandro SonninoAbstract In this report we show, by confocal analysis of
indirect immunoﬂuorescence, that the type-1 cannabinoid recep-
tor (CB1R), which belongs to the family of G-protein-coupled
receptors, is expressed on the plasma membrane in human breast
cancer MDA-MB-231 cells. However, a substantial proportion
of the receptor is present in lysosomes. We found that CB1R
is associated with cholesterol- and sphyngolipid-enriched mem-
brane domains (rafts). Cholesterol depletion by methyl-b-cyclo-
dextrin (MCD) treatment strongly reduces the ﬂotation of the
protein on the raft-fractions (DRM) of sucrose density gradients
suggesting that CB1 raft-association is cholesterol dependent.
Interestingly binding of the agonist, anandamide (AEA) also
impairs DRM-association of the receptor suggesting that the
membrane distribution of the receptor is dependent on rafts
and is possibly regulated by the agonist binding. Indeed MCD
completely blocked the clustering of CB1R at the plasma mem-
brane. On the contrary the lysosomal localization of CB1R was
impaired by this treatment only after AEA binding.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The cannabinoid type I receptor (CB1R), a seven-transmem-
brane domain protein, is one of the most abundant G-protein-
coupled receptors (GPCRs) in the central nervous system and
in some peripheral tissues [1–3]. High levels of the CB1 recep-
tor are found in hippocampal neurons which also contain theAbbreviations: AEA, anandamide; Cav1, caveolin 1; DRMs, deter-
gent-resistant microdomains; MCD, methyl-b-cyclodextrin; GPCRs,
G-protein-coupled receptors; TNE/TX-100, Tris Na EDTA/Triton
X-100 buﬀer; PBS, phosphate buﬀer saline
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mide (anandamide; AEA) [4]. Together with AEA and congen-
ers like 2-arachidonoylglycerol, CB1 and CB2 receptors form
the ‘‘endocannabinoid system’’ which regulates several biolog-
ical events such as vascular relaxation, apoptosis and cell pro-
liferation in human breast cancer cells [5]. Indeed, we have
previously observed that AEA inhibits the proliferation of
human breast cancer cells (HBCCs) by blocking the G0/G1–S
phase transition of the cell cycle through interference with
CB1 receptor-coupled signal transducing events [6] indicating
that endocannabinoids can act as selective inhibitors of human
breast cancer cell proliferation through a growth-factor-depen-
dent mechanism [7].
We have also shown that a metabolically stable AEA analog
(Met-F-AEA) stops the growth of K-ras-dependent tumors,
induced and/or already established, in vivo and it inhibits
metastatis in the Lewis lung carcinoma model, two eﬀects that
are mediated by CB1 receptors [8,9]. Furthermore we observed
that endocannabinoids can induce a non-invasive phenotype in
human breast metastatic cells MDA-MB-231 (Bifulco et al.,
personal communication).
The termination of the endocannabinoid signaling as well as
the molecule(s) and the mechanism(s) responsible for the bio-
synthesis, release and uptake of AEA have not yet been eluci-
dated [3].
CB1Rs are coupled to Gi/0-proteins which, once activated by
the binding of the ligand agonist, initiate various changes in
intracellular signalling pathways. It has been reported that
the CB1 receptor, like many, but not all G-protein-coupled
seven-transmembrane receptors, could undergo agonist-
induced [10,11] or constitutive endocytosis [12] cycling between
the plasma membrane and endosomes. However, the mecha-
nism of CB1R internalization is not completely understood
although recent ﬁndings suggest that both clathrin-coated pits
and caveolae might be involved in this process [13]. In addi-
tion, it has been shown that the cellular accumulation of its
ligand AEA is possibly due to caveolae-mediated endocytosis
in RBL-2H3 cells [14] and that methyl-b-cyclodextrin
(MCD), which extracts cholesterol from the plasma mem-
brane, completely blocks AEA-induced cell death in a variety
of cells, including PC12, C6, HEK and HL-60 cells [15]. All
these data point towards an involvement of caveolae and of
cholesterol-enriched membrane domains in the traﬃckingblished by Elsevier B.V. All rights reserved.
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in AEA-depending signaling was suggested [15,16].
Lipid rafts are membrane domains biochemically deﬁned by
the insolubility of their components in cold non-ionic deter-
gents (like Triton X-100) [17,18]. They are enriched in speciﬁc
lipids characterized by their saturated long fatty acid chains,
like sphingomyelin and sphingolipids, and by cholesterol.
Because of their ability of forming more liquid ordered do-
mains within the membranes, lipid rafts also segregate partic-
ular proteins and regulate their intracellular traﬃcking and
signal transduction functions within [19].
Caveolin 1 (Cav1), one of the ﬁrst protein found to be
enriched in rafts, oligomerizes to form the proteinaceous coat
of caveolae [20], ﬂask-shaped invaginations of the plasma
membrane, which represents a subset of organized raft
domains [21]. Besides their recognized role in endocytosis, cav-
eolae have been implicated in serving many functions, includ-
ing the organization of key signalling proteins, cholesterol
transport, and potocytosis [20,22].
Both lipid rafts and caveolae are dependent on cholesterol
and are disrupted by drugs extracting cholesterol from the
plasma membrane, like MCD. Although cholesterol depletion
experiments indicated a possible role of both these domains in
the traﬃcking and signalling of CB1R, the molecular mecha-
nism of AEA uptake, the relationship with CB1 receptor and
the cellular compartments involved in the signal transduction
events deriving from their interaction are not yet deﬁned and
even less is known about the cellular mechanisms controlling
CB1R intracellular traﬃcking and signaling.
Therefore, we studied the subcellular distribution of the
CB1R in basal conditions, as well as its traﬃcking in response
to agonist stimulation in human breast cancer MDA-MB-231
cell line because of a role of lipid rafts in the regulation of
breast tumor cell invasion [23].
In the present study we have investigated the localization of
CB1R in human breast cancer MDA-MB-231 cells, and exam-
ined whether CB1R was associated with lipid rafts by utilizing
both immunocytochemistry studies and biochemical analysis.
We found that CB1R is associated with lipid rafts and is local-
ized both on the cells surface and in the lysosomal compart-
ment of MDA-MB-231 cells. We also show that the surface
clustering of CB1R is dependent on rafts integrity, while its
lysosomal localization is impaired by cholesterol depletion
only when the receptor is bound to its agonist AEA.2. Materials and methods
2.1. Reagents and antibodies
Cell culture reagents were purchased from Gibco Laboratories
(Grand Island, NY). The anti-CB1R antibody was from Santa Cruz
Biotechnology and anti-Cav1 antibody was purchased from BD Bio-
sciences. The antibodies against BiP, Giantin and LysoTracker from
StressGen Biotechnologies Corp. (120-4243 Glanford Ave. Victoria,
BC, Canada). Met-F-AEA (2-methyl-2 0-F-anandamide) and MCD
were purchased from Sigma–Aldrich.
2.2. Reverse transcriptase polymerase chain reaction
Total RNA was extracted from cell lines by guanidinum thiocya-
nate–isopropanol method. Reverse transcription (RT) was performed
using Moloney murine leukaemia virus reverse transcriptase and
random oligonucleotide primers. The ﬁrst strand cDNA was then
ampliﬁed using two diﬀerent sets of primers. The sense primer
CB1-F (5 0-GATGTCTTTGGGAAGATGAACAAGC-3 0) and theantisense primer CB1-R (5 0-GACGTGTCTGTGGACACAGAC-
ATGG-3 0) were used to amplify the CB1 receptor; the primers for
ampliﬁcation of alpha actinin were A1F (5 0-ATGATCTGGACCAT-
CATCCT-3 0) and A1R (5 0-CTRATGTGGAAGTTRTGCATG-3 0).
Polymerase chain reactions were performed 30 s at 93 C, 1 min at
59 C and 1 min at 69 C for 25–28 cycles. Ampliﬁed DNA was
extracted with chloroform and electrophoresed in a 2% agarose gel
in 0.5· TBE.2.3. Western blot analysis
Cells plated in 100 mm dishes in regular medium with serum were
washed with ice-cold phosphate buﬀer saline (PBS) and scraped into
lysis buﬀer (50 mM Tris–HCl, 150 mM NaCl, 0.5% Triton X-100,
0.5% deossicolic acid, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl
ﬂuoride, 10 mg/ml aprotinin). After removal of cell debris by centrifu-
gation (4000 · g, 5 min), about 50 lg of proteins were loaded on 12%
SDS–polyacrylamide gels under reducing conditions. After SDS–
PAGE, proteins were transferred to nitrocellulose membranes that were
blocked with 5%milk (Bio-Rad Laboratories, Inc., Richmond CA) and
incubated with anti-CB1R antibody. After three washes, ﬁlters were
incubated for 1 h at room temperature with horseradish peroxidase-
conjugated goat antirabbit secondary antibody. The membranes were
then stained using a chemiluminescence system (ECL-Amersham
Biosciences) and then exposed to X-ray ﬁlm (Kodak).2.4. Immunoﬂuorescent staining
Cells were plated in 24-well plates on coverslips (Becton–Dickinson
Labware). When they were 60 ± 80% conﬂuent, they were treated with
Met-F-AEA (10 lM 24 h), and/or MCD (10 mM, 15 min). After the
incubation with various drugs, the cells were washed twice with PBS
and ﬁxed in 3.7% paraformaldehyde in PBS for 20 min and followed
by two washes in 50 mM NH4Cl for 10 min. Permeabilization was
achieved by incubating the ﬁxed cells in 0.1% Triton X-100 in PBS
for 5 min at room temperature. The cells were then blocked in FDB
buﬀer (1 mM MgCl2, 1 mM CaCl2, 5% foetal calf serum and 2%
BSA in PBS) for 30 min at room temperature. All primary and second-
ary antibody incubations were performed in FDB buﬀer for 1 h at
room temperature. Coverslips were mounted on 50% glycerol in PBS
and examined by using a Zeiss Laser Scanning Confocal Microscope
(LSCM 410 or 510).2.5. Drugs treatment
MCD treatment was carried out as described elsewhere [24]. Brieﬂy,
MDA-MB-231 cells were plated on dishes and MCD (10 mM) was
added to the medium containing 20 mMHEPES, pH 7.5, and 0.2% bo-
vine albumin for 15 min at 37 C. Met-F-AEA (10 lM) was added to
the complete culture medium for 24 h. Where indicated, the cells were
ﬁrst cholesterol depleted by MCD (10 mM, 15 min at 37 C) and then
extensively washed and incubated with Met-F-AEA for further 24 h.
2.6. Cholesterol determination
In order to assay cholesterol levels in the cells before and after treat-
ment with MCD we used the following method: MDA-MB-231 cells
grown in the presence or absence of MCD were washed twice with
PBS, lysed with appropriate lysis buﬀer and Inﬁnity Cholesterol
Reagent (Sigma Chemical Co., St. Louis, MO, code number 401-25
P) was added to the lysates in the ratio 1:10 for 5 min at 37 C (accord-
ing to the suggested Sigma protocol number 401). The samples were
then measured in a spectrophotometer at 550 nm.2.7. Assays for DRM-association
OptiPREPe density gradients: OptiPREPe gradient analysis of TX-
100-insoluble material was performed using previously published pro-
tocols [25]. Cells were grown to conﬂuence in 100 mm dishes, washed
in PBS C/M and lysed for 20 min in TNE/TX-100 1% buﬀer (25 mM
Tris–HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 1% TX-100) on
ice. Lysates were scraped from dishes, brought to 40% OptiPREPe,
and then placed at the bottom of a centrifuge tube. A OptiPREPe gra-
dient (5–35% TNE) was layered on top of the lysates and the samples
were centrifuged at 21000 rpm, at 4 C for 4 h in an ultracentrifuge
(model SW41 Beckman Inst., Fullerton, CA). One-milliliter fractions
were harvested from the top of the gradient. CB1R was revealed by
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lipid rafts isolation, Cav1 was chosen as raft marker and Bip as non-
raft marker.3. Results
3.1. Characterization of CB1R expression and localization in
MDA-MB-231 cells
In order to analyze the expression levels of CB1R in MDA-
MB-231 cells we ﬁrst analyzed its mRNA expression level by
reverse transcriptase-PCR (RT-PCR) technique. We found
that CB1R was expressed in our cell system and by Western
blot analysis, using a speciﬁc antibody against CB1R on cell
lysates, we corroborated these data showing that MDA-MB-
231 cells expressed high signiﬁcative levels of CB1R (Fig. 1).
We next analyzed the cellular localization of CB1R by indi-
rect immunoﬂuorescence and confocal microscopy on cells
grown on coverslips. In non-permeabilized conditions CB1R
was localized on the plasma membrane of MDA-MB-231 cells
mainly concentrated in large spots (Fig. 2A).
In permeabilized conditions, by using markers of diﬀerent
intracellular compartments, such as giantin for the Golgi com-
plex, Bip for the endoplasmic reticulum, early endosome anti-
gen-1 for early endosomes (data not shown) and LysoTracker
to label lysosomes, we found that the receptor was widely dis-
tributed in the cytoplasm and was particularly concentrated in
lysosomes as shown in the merged signal from the anti-CB1R
antibody and LysoTracker (Fig. 2B). In line with these results,
it has been demonstrated that many signaling receptors, such as
the G-protein-coupled d opioid receptor, can undergo agonist-
induced proteolysis via endocytic traﬃcking to lysosomes [26].
After activation, most GPCRs are endocytosed from the cell
surface and travel to low pH endosomes, leading the ligand to
detach before the receptor is recycled back to the cell surface orFig. 1. Expression levels of CB1R in MDA-MB-231 cells. Cells grown
in RPMI 1640 medium supplemented with 10% inactivated foetal
bovine serum and 2 mM L-glutamine were subjected to total RNA
extraction and reverse transcription (RT) was performed using
Moloney murine leukaemia virus reverse transcriptase and random
oligonucleotide primers for CB1R and actinin were used. Polymerase
chain reactions were performed 30 s at 93 C, 1 min at 59 C and 1 min
at 69 C for 25–28 cycles to assess saturation of the signal (left panel,
RT-PCR). The cells grown in the same conditions described above,
were scraped in lysis buﬀer and 50 lg proteins were subjected to SDS–
PAGE. CB1R was revealed by Western blotting on nitrocellulose and
hybridization with monoclonal anti-CB1R antibody in 5% milk (right
panel, Western blot: WB).sent to the lysosomes for degradation [27]. It has been hypoth-
esized that traﬃcking of GPCRs from early endosomes to
lysosomes might be a mechanism for agonist-induced down-
regulation. Indeed, several GPCRs, including the thrombin,
thyrotropin and cholecystochinin receptors, have been shown
to be sorted to lysosomes in an agonist-dependent manner
[28]. Contrary to these ﬁndings, we found CB1R in lysosomal
structures even in absence of its ligand, that is in basal condi-
tions (Fig. 2B).
Lipid rafts represent versatile devices for compartmentaliz-
ing cellular membrane processes and form large platforms
involved in protein and lipid signaling, processing and trans-
port [19,29,30].
Because raft domains exist both at the plasma membrane and
lysosomes [31], and a lysosomal degradative pathway for CB1
receptor has not yet been demonstrated, we sought to analyze
whether the intracellular compartmentalization of CB1R was
dependent on lipid rafts. To this aim we studied the intracellular
distribution of CB1R after lipid rafts disruption by cholesterol
depletion. Cholesterol is an important functional and structural
component of lipid rafts and its depletion by using diﬀerent
drugs has been demonstrated to alter the raft composition and
as a consequence the raft functions [17,32]. After incubation
with MCD which extracted 60% of the total cholesterol (see
Section 2), we found that lysosomal localization of CB1R was
not aﬀected as shown by colocalization with LysoTracker
(Fig. 2B, MCD, see merge in the right panel). On the contrary,
cholesterol depletion strongly altered the cell surface CB1R
localization inducing a more uniform plasma membrane distri-
bution of the receptor (Fig. 2C). These data suggest that the plas-
ma membrane clustering of CB1 is dependent on lipid rafts,
while the receptor does not appear associate to cholesterol-
dependent domains in the lysosomes. Thus, these results indicate
that lipid rafts donot appear to regulate the route ofCB1R to the
lysosomes where presumably degradation of CB1R occurs.3.2. CB1R localization after anandamide treatment
Several endogenous ligands for cannabinoid receptors have
been identiﬁed, most notably anandamide (AEA) and noladin
ether.
Because the nature of CB1R interaction with AEA, as well
as the exact cellular site for their interaction are not yet known,
we decided to study the eﬀect of anandamide on CB1R intra-
cellular localization, by using its synthetic analogous metha-
nandamide (Met-F-anandamide) which is more stable to the
fatty acid amide hydrolase hydrolysis than the anandamide
itself [33].
As shown by immunoﬂuorescence in permeabilized condi-
tions (Fig. 3), the presence of Met-F-AEA (10 lM, for 24 h)
added to the extracellular medium did not change the intracel-
lular distribution of CB1R (compare Fig. 3, AEA, with Fig. 2B,
control). Interestingly, pre-treatment with MCD (10 mM for
15 min at 37 C) before agonist incubation, signiﬁcantly chan-
ged the intracellular distribution of the receptor which assumed
a more diﬀuse cytoplasmic localization and lost its lysosomal
localization (see Fig. 3, MCD + AEA). Thus, these data indi-
cate that the presence of the agonist modiﬁes the intracellular
localization of the receptor when lipid rafts are perturbed by
cholesterol depletion, suggesting that the intracellular pathway
followed by CB1R to the lysosomes, after the binding of the li-
gand anandamide, is depending on lipid rafts integrity.
Fig. 2. Surface distribution and intracellular localization of CB1R. (A) The cells were grown on coverslips and ﬁxed with paraformaldehyde. CB1R
was revealed by incubating the cells with the ﬁrst antibody and then with TRITC-conjugated secondary antibody under non-permeabilized
conditions. (B) The cells were grown on coverslips without (control) or with MCD for 15 min at 37 C and were incubated 1 h with LysoTracker
1:10000 in complete culture medium. They were then ﬁxed, permeabilized with TX-100 (see Section 2) and CB1R was revealed with a FITC-
conjugated secondary antibody. All the immunoﬂuorescence samples were observed using a Laser Scan Confocal microscope as described in Section
2. The yellow spots indicate that lysosomes and CB1R colocalize. (C) Cells were subjected to immunoﬂuorescence analysis as in A, with the exception
that here the cells were analyzed after cholesterol depletion with MCD (15 min at 37 C). Bar: 10 lm.
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detergent-resistant microdomains
Association of CB1R with lipid rafts has not yet been for-
mally demonstrated. Thus, we analyzed whether it was associ-
ated with detergent-resistant microdomains (DRMs) by
performing TX-100 extraction and ﬂotation-based assays (see
Section 2). Indeed, resistance to non-ionic detergent extraction
at 4 C (e.g., TX-100) and association with DRMs is one of the
major biochemical characteristics of lipid rafts and raft com-
ponents [22,34–36]. We found that CB1R was TX-100 insolu-
ble at steady-state (not shown) and speciﬁcally 80% of the
receptor ﬂoated in the fractions 4–5 of the gradients, which
are the typical DRMs containing fractions (Fig. 4A, control),
as shown by the ﬂotation of Cav1, an extensively characterized
raft marker (Fig. 4A, Cav1) [23]. In particular, Western blot
analysis on an aliquot of the individual fractions, conﬁrmed
an enrichment of Cav1 in fraction 5 (Fig. 4A), conﬁrming thatwe had successfully isolated DRM-domains. We also veriﬁed
that a typical non-raft marker, the endoplasmic reticulum res-
ident protein Bip/GRP78, was excluded from these fractions
(Fig. 4A). Of note, the prevalent enrichment of both CB1
receptor and Cav1 in the high density fraction 5 more than
in fraction 4 of the gradient (Fig. 4A, control) suggested
that the two proteins were distributed in lipid rafts of similar
density.
Because cholesterol is an important structural and func-
tional component of rafts [17,29], we determined whether
CB1R raft-association was cholesterol-dependent. After treat-
ment with MCD (10 mM, 15 min 37 C), the amount of CB1R
present in the lighter fractions (fractions 4 and 5) of the gradi-
ent signiﬁcantly decreased, and it was estimated to be 10% of
the total amount of protein distributed in the gradient (Fig. 4
and compare fractions 4–5 of the control with fractions 4–5 of
the MCD treatment). As expected and previously shown in
Fig. 3. Localization of CB1R after Met-F-AEA incubation in control or cholesterol depleted cells. MDA-MB-231 cells were grown on coverslips in
culture medium containing Met-F-AEA (10 lM, 24 h). Where indicated, the cells were ﬁrst cholesterol depleted with MCD and then treated with
Met-F-AEA (see Section 2). CB1R was revealed by indirect immunoﬂuorescence analysis as in Fig. 2B. Samples were observed using a Laser Scan
Confocal microscope. Bar: 10 lm.
Fig. 4. Puriﬁcation of CB1R on OptiPREPe density gradients and eﬀect of MCD and anandamide on CB1R raft-association. (A) The cells were
grown in 100 mm dishes in control conditions. They were then lysed for 20 min in cold TNE/TX-100 buﬀer and then run through a ‘‘Two Step’’
OptiPREPe gradient (5–40% gradient). One-milliliter fractions were collected from the top of the gradient after centrifugation to equilibrium. An
aliquot of each fraction was loaded on 12% gel and revealed by Western blotting and ECL. The distribution of Cav1 and Bip was analyzed by
Western blot, respectively, with the anti-Cav1 and anti-Bip antibody and ECL. (B) CB1R puriﬁcation from the OptiPREPe gradients was performed
after cholesterol depletion with MCD. CB1R, Cav1 and Bip were revealed following the procedure described above. (C) The cells were grown in
100 mm dishes and treated with Met-F-AEA in control condition or after cholesterol extraction by MCD (MCD + AEA) and they were then
subjected to puriﬁcation of CB1R, Cav1 and Bip from OptiPREPe density gradient fractions. An aliquot of each fraction was loaded on 12% gel,
separated with SDS–PAGE and revealed by Western blot and ECL. (D) Quantiﬁcation of the amount of CB1R in the raft fractions 4 and 5 of the
gradients, in diﬀerent indicated conditions, is reported as a percentage of the total amount of the protein in the gradient and was performed by a
densitometric analysis of the bands by NIH image program for McIntosh. Error bars are indicated in the graph and represent the average of three
independent experiments.
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was a signiﬁcant reduction of the raft marker Cav1 in the lipid
raft fraction (fractions 4–5) but not of the non-raft protein Bip
(Fig. 4B). These ﬁndings suggest that both CB1R and Cav1
raft-association are dependent on cellular cholesterol levels.
3.4. Eﬀect of anandamide on CB1R raft-association
In order to directly test the inﬂuence of the CB1R agonist on
its raft-association, we included the metabolically stable
anandamide analogue Met-F-AEA in the culture medium of
MDA-MB-231 cells and then performed the ﬂotation assay.
We found that 50% of total CB1R ﬂoated in the DRM-frac-
tions (Fig. 4C and D, see fractions 4–5 AEA) in the presence of
the ligand. Thus, diﬀerently from basal conditions in which
80% of the receptor was found in the light fractions 4–5
(Fig. 4A, control), the anandamide binding lead to a redistri-
bution of the receptor in the soluble fractions of the gradient
(fractions 8–12). It is noted that after AEA treatment, Cav1
and Bip distribution in the OptiPREPe preparation was the
same of the control condition suggesting that, AEA aﬀects spe-
ciﬁcally CB1R raft-association inducing a decrement of CB1R
ﬂotation which was exclusively related to fraction 5. Further-
more, contrarily to CB1R, we found that the ﬂotation proﬁle
of Cav1 was not aﬀected by AEA but exclusively dependent
on cholesterol. After MCD treatment, in the presence of its
agonist only 20% of CB1R ﬂoated in the OptiPREPe gradi-
ent and interestingly the majority of the receptor accumulated
in the fraction 8 (non-raft membrane) (Fig. 4C, MCD + AEA
and 4D and compare with Fig. 4A, control). These results
clearly suggest that the proﬁle of CB1R distribution in the gra-
dient fractions is aﬀected by its ligand. Cholesterol depletion
further reduces the ﬂotation of the receptor indicating that
part of the AEA binding could occur in cholesterol sensitive
domains.4. Discussion
We have investigated the intracellular localization of CB1R
and its association with lipid rafts in order to elucidate how the
presence of its ligand anandamide and the intracellular choles-
terol levels aﬀect CB1R traﬃcking in a human breast cancer
cell line.
It has been previously shown that in HEK-293 cells, as well
as in LLC-PK1 epithelial cells or SHSY-5Y neuroblastoma
cells, CB1R is predominantly localized in endosomes at steady-
state [37], as a result of a constitutive recycling between the
plasma membrane and endosomes, mediated by the small
GTPases Rab5 and Rab4 [12,38]. By confocal analysis of indi-
rect immunoﬂuorescence we found that CB1R is expressed on
the plasma membrane of MDA-MB-231 cells. However, a sub-
stantial proportion of the receptor is present in lysosomes
(Fig. 2B). Thus, diﬀerently from the previous reports [12,38],
at our knowledge we provide the ﬁrst evidence for a lysosomal
localization of this receptor in the cells.
Lysosomes are structures with diﬀerent kind of critical func-
tions. Among these, the main lysosomes functions could be
summarized as follow: (1) the lysosomes can operate enzymatic
digestion of endocytosed materials; (2) can mediate events in
the programmed cell death called apoptosis; (3) can play an
important role in receptor-mediated endocytosis and mediate
events of receptor recycling and the shutting down of eventsof cell communication [39]. This sequence of events involves
a receptor binding to its ligand followed by their uptake into
coated vesicles. Hence, our ﬁnding that CB1R shows a lyso-
somal localization could represent fundamental basis to fur-
ther studies about receptor internalization, downregulation
and eventual resensitization which constitute essential steps
to analyze receptors function and signalling within the cells.
For several receptors, the cellular responses to eﬀectors have
been shown to be regulated in part by the compartmentaliza-
tion of the receptors and their eﬀectors within the cells [40],
therefore elucidating the mechanism underlying the traﬃcking
of CB1R is critical for understanding the physiological
response to a variety of ligands.
Interestingly, we found a signiﬁcant change in CB1R cell sur-
face distribution after cholesterol depletion by MCD. Indeed,
the clustered distribution of the receptor at the cell surface
was lost and it assumed a more diﬀuse staining thus indicating
that the plasma membrane clustering of CB1R was dependent
on cholesterol-enriched microdomains (lipid rafts or DRMs).
It remains to be established whether the CB1 cholesterol-depen-
dent plasma membrane localization is of any functional signif-
icance in regulating CB1-mediated signalling.
It has been reported that cholesterol depletion by MCD can
aﬀect the transport of cholera toxin from endosomes to Golgi
but not from Golgi to lysosomes [41]. The reason that choles-
terol can regulate some transport steps but not others is un-
known, but presumably depends on cholesterol levels in the
compartments/vesicles that mediate transport. In addition cho-
lesterol depletion can alter the internalization pathways of dif-
ferent surface receptors [42].
In the case of CB1R, at least in our cell system, cholesterol
depletion alters its plasma membrane localization but not the
lysosomal one, thus we propose that the receptor might exhibit
a diﬀerent mode of interaction with the membrane lipid bilayer
of the plasma membrane respect to that of lysosomal mem-
branes. This hypothesis is supported by the ﬁnding that diﬀer-
ent kinetics and sorting of lipid analogs out of endosomes
depend exclusively on their hydrophobic chains [43]. Further-
more, while on one hand cholesterol depletion did not alter the
receptor lysosomal localization in control conditions, on the
other hand induced a remarkable redistribution of CB1R in
the cytoplasm and an impairment of the receptor lysosomal
localization after extracellular addition of the agonist ananda-
mide (see Fig. 3). These results indicate that the intracellular
pathway followed by CB1R to the lysosomes after binding
of the agonist might depend on lipid rafts. Further detailed
analysis will be necessary to understand whether this results
come from an impairment of the CB1R endocytic pathway
that normally directs the receptor to the lysosomal route for
its processing, or whether under cholesterol depletion there is
also a mis-sorting of the newly synthesized protein.
Based on cholesterol depletion studies it has been proposed
that lipid rafts might have a crucial role in both AEA uptake/
recycling [14] and AEA-induced apoptosis [15,16,44]. How-
ever, these experiments did not address whether and how lipid
depletion aﬀected CB1R localization, its raft-association and
the regulation of CB1R-dependent signaling by the agonist
anandamide.
Thus, in order to test the hypothesis that lipid rafts might be
involved in CB1R traﬃcking in high invasive human breast
cancer cell line MDA-MB-231, in which we have previously
observed that endocannabinoids regulates cell proliferation
D. Sarnataro et al. / FEBS Letters 579 (2005) 6343–6349 6349and can induce a non-invasive phenotype, we analyzed the
raft-association of the CB1 receptor in these cells. We found
that CB1R was associated with DRMs and that cholesterol
depletion by MCD decreases its raft-association, which was
also diﬀerently controlled by the presence of its agonist
anandamide. We found that Met-F-AEA reduces signiﬁcantly
CB1R DRM-association both in the absence or presence of
MCD (Fig. 4C and D).
In this contest, our observation that cholesterol depletion,
before AEA incubation displaces CB1R from rafts and causes
an intracellular redistribution, is particularly intriguing be-
cause recent evidences suggest that the cellular uptake of
anandamide could be mediated by lipid rafts [14] and that
MCD treated CB1R-expressing C6 cells are protected from
AEA-induced apoptosis [15,44]. Complementarily with these
data, we show for the ﬁrst time that CB1R is associated with
DRMs and suggest that they might represent a cellular device
for its intracellular traﬃcking as well as favorable platform to
regulate CB1R signalling.
We are currently checking the implication of lipid rafts/cave-
olae for the signalling of CB1R and whether the data described
in this report could give signiﬁcant clues to study the endocan-
nabinoid system. However because endocannabinoids through
CB1R-dependent mechanism have been shown to have a role in
cancer [45,46] and lipid rafts play a pivotal role in breast tumor
cell invasion [23], the current data support the view that pertur-
bation of lipid rafts may represent a useful tool to control CB1R
signalling and could lead to the development of a novel therapy
for endocannabinoids-related diseases, such as cancer.
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